Can FeNO be a biomarker in the post-COVID-19 patients monitoring?
FeNO
Post-COVID-19
biomarker
Journal
Respiratory medicine
ISSN: 1532-3064
Titre abrégé: Respir Med
Pays: England
ID NLM: 8908438
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
received:
02
11
2021
revised:
11
01
2022
accepted:
17
01
2022
pubmed:
4
2
2022
medline:
3
3
2022
entrez:
3
2
2022
Statut:
ppublish
Résumé
The nature of the inflammatory and fibrotic processes found in patients with post-COVID-19 syndrome makes it possible to speculate that in such patients fractional exhaled nitric oxide (FeNO) may be a useful biomarker. Consequently, we set out to verify the consistency of this hypothesis. We consecutively enrolled 68 post-COVID patients after being hospitalized for persistent clinical manifestations within 2 months from disease onset and 29 healthy volunteers as control group. None of post-COVID patients had bronchial asthma or were being treated with a corticosteroid. Only 19 out of 68 post-COVID-19 patients reported a FeNO value > 25 ppb. The mean FeNO value in post-COVID-19 patients was 18.55 ppb (95% CI: 15.50 to 21.58), while in healthy subjects it was 17.46 ppb (95% CI: 15.75 to 19.17). The mean difference was not statistically significant (P = 0.053). However, the mean FeNO value of post-COVID-19 patients was higher in men than in women (20.97 ppb; 95% CI: 16.61 to 25.33 vs 14.36 ppb; 95% CI: 11.11 to 17.61) with a difference between the two sexes that was statistically significant (P = 0.016). Mean FeNO was 14.89 ppb (95% CI: 10.90 to 18.89) in patients who had been treated with systemic corticosteroids because of their COVID-19, and 20.80 ppb (95% CI: 16.56 to 25.04) in those who had not taken them, with a difference that was statistically significant (P = 0.043). The data generated in this study suggest that measurement of FeNO is not useful as a biomarker in post-COVID-19 patient. However, this hypothesis needs solid validation with additional specifically designed studies.
Identifiants
pubmed: 35114576
pii: S0954-6111(22)00010-5
doi: 10.1016/j.rmed.2022.106745
pmc: PMC8789557
pii:
doi:
Substances chimiques
Biomarkers
0
Nitric Oxide
31C4KY9ESH
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
106745Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.
Références
Int J Gen Med. 2021 Jul 09;14:3271-3280
pubmed: 34267545
BMJ. 2020 Aug 11;370:m3026
pubmed: 32784198
BMC Pulm Med. 2017 Aug 25;17(1):118
pubmed: 28841881
Am J Respir Crit Care Med. 2005 Apr 15;171(8):912-30
pubmed: 15817806
BMJ. 2007 Oct 20;335(7624):806-8
pubmed: 17947786
Respir Med. 2021 Jan;176:106276
pubmed: 33278758
J Investig Allergol Clin Immunol. 2022 Jul 22;32(4):301-303
pubmed: 34755657
Respir Med. 2021 Jun;182:106401
pubmed: 33873099
Thorax. 2006 Sep;61(9):744-6
pubmed: 16936234
Respir Med. 2020 Nov;173:106156
pubmed: 32979621
Cell. 2021 Jan 7;184(1):149-168.e17
pubmed: 33278357
J Allergy Clin Immunol Pract. 2015 Nov-Dec;3(6):913-9
pubmed: 26216254
Ann Med. 2021 Dec;53(1):1659-1672
pubmed: 34528479
Microorganisms. 2021 Feb 08;9(2):
pubmed: 33567583
Vaccines (Basel). 2021 May 12;9(5):
pubmed: 34066007
Cell Immunol. 2013 May-Jun;283(1-2):1-7
pubmed: 23831683
J Allergy Clin Immunol. 2020 Jul;146(1):1-7
pubmed: 32344056
Respir Res. 2007 Nov 15;8:82
pubmed: 18005450
Respir Res. 2021 Aug 26;22(1):237
pubmed: 34446020
Am J Respir Crit Care Med. 2021 May 15;203(10):1319-1322
pubmed: 33684323
Am J Respir Crit Care Med. 2021 Dec 1;204(11):1345-1347
pubmed: 34491873
Respir Med. 2014 Jun;108(6):830-41
pubmed: 24636813
Am J Respir Crit Care Med. 2011 Sep 1;184(5):602-15
pubmed: 21885636
Respir Investig. 2021 Jan;59(1):34-52
pubmed: 32773326
Int J Mol Sci. 2020 Aug 27;21(17):
pubmed: 32867116
Ann Lab Med. 2021 Nov 1;41(6):540-548
pubmed: 34108281
Antioxidants (Basel). 2021 Aug 25;10(9):
pubmed: 34572982
Eur Respir J. 1998 Jan;11(1):126-32
pubmed: 9543281
J Breath Res. 2020 Dec 05;15(1):014001
pubmed: 33080582
Immunol Rev. 2021 Jul;302(1):228-240
pubmed: 34028807